– In a dramatic escalation of the fight over U.S. drug prices, President Donald Trump’s administration has given the pharmaceutical industry a stark ultimatum: lower prescription costs for American patients within 60 days or face aggressive federal intervention.
The White House announced this sweeping demand through 17 letters sent directly to the CEOs of the world’s largest pharmaceutical companies. The message, read aloud by Press Secretary Karoline Leavitt
during a briefing, left little room for negotiation.
“If you refuse to step up, we’ll deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,” the letters warned.
The move marks one of the most ambitious attempts yet by any U.S. administration to take on pharmaceutical giants, signaling that the president intends to make prescription affordability a defining policy battle in his second term.
At the heart of the ultimatum is Trump’s insistence on “Most-Favored-Nation” (MFN) pricing. The principle is simple: Americans should not be paying more for the same drugs than patients in other wealthy countries.
Currently, U.S. patients often pay two to three times as much for life-saving medications compared to Europe or Canada. According to federal health data, the United States spends more per capita on prescription drugs than any other nation. Nearly
Trump’s MFN policy, outlined in an executive order signed in May, demands that drugmakers extend their lowest global price to U.S. markets. The administration’s letters expand this requirement to include:
Medicaid recipients – ensuring the poorest Americans benefit directly.
Newly launched drugs – requiring companies to set initial prices in line with their cheapest global rate.
Revenue repatriation – calling on firms to return profits from inflated foreign prices to support American patients.
Direct purchasing options – allowing patients to buy medications at MFN rates, bypassing middlemen like pharmacy benefit managers (PBMs).
“Global freeloading ends with this administration,” Trump wrote in his letter to Eli Lilly’s CEO, David Ricks.
The pharmaceutical industry responded with a mix of alarm and guarded statements. Stocks in several major firms—including Pfizer, Merck, and Johnson & Johnson—dipped briefly following the announcement, though most rebounded within hours. Analysts suggested markets were betting on the industry’s ability to resist or dilute the reforms.
Industry lobbyists argue that tying U.S. drug prices to international benchmarks could cripple innovation, warning it would reduce funding for research and development of new treatments.
“The American system is what fuels medical breakthroughs,” one pharmaceutical executive said anonymously. “If our pricing flexibility disappears, so does the next generation of cures.”
Yet critics counter that this line has been used for decades to justify runaway profits. According to federal data, the pharmaceutical sector consistently ranks among the most profitable industries in the United States, often posting double-digit margins.
This is not Trump’s first battle with the drug industry. During his first term, he launched initiatives aimed at price transparency and international reference pricing, but most were either watered down or struck down in court.
The difference this time is both political capital and public pressure. Trump won reelection in 2024 promising to slash drug costs, and soaring prices have remained a top concern for voters across party lines. Polls show overwhelming bipartisan support for government action to curb costs.
The administration is also framing the issue as a matter of economic fairness. Trump has repeatedly claimed that American patients are “subsidizing” low prices abroad, where governments negotiate aggressively with drugmakers while U.S. consumers are left to pay the balance.
“Other nations negotiate, and they get a good deal. We don’t negotiate—we pay whatever Big Pharma asks,” Trump said in a recent rally. “That ends now.”
The 60-day window is designed to force immediate responses while aligning with the fall legislative calendar. By setting a hard deadline, the White House increases pressure on both industry executives and members of Congress.
If drugmakers fail to present binding commitments, the administration has hinted at multiple options:
Regulatory changes through the Department of Health and Human Services (HHS).
Direct government negotiations on behalf of Medicare and Medicaid.
Expanded executive orders tying pricing to federal purchasing power.
Potential trade measures against companies deemed to be exploiting U.S. markets.
The ultimatum also sets up a potential legal showdown. Industry groups are already preparing lawsuits arguing that MFN pricing violates constitutional protections and international trade rules.
For Trump, the move is both politically risky and potentially rewarding. Successfully cutting drug prices would deliver a tangible benefit to millions of Americans, strengthening his populist brand.
But failure—or even the perception of capitulation to Big Pharma—could erode trust among his base.
Democrats, traditionally more supportive of drug pricing reforms, face a tricky political choice. Many support the idea of lowering costs but are reluctant to hand Trump a political victory. Some progressive lawmakers are already pushing for
Meanwhile, Republican lawmakers are split. Fiscal conservatives worry about government overreach, while populist conservatives embrace the plan as a way to stand up to corporate power.
If the policy is enforced, the ripple effects could be felt worldwide. Drugmakers may respond by raising prices abroad to offset U.S. cuts, creating tension with European and Canadian governments.
Health economists also warn of a possible two-tiered system: companies could prioritize releasing new drugs in countries willing to pay higher launch prices, delaying access for others.
However, supporters argue that forcing international parity would finally put American patients on equal footing, ending decades of lopsided pricing.
Drug pricing is only one piece of the U.S. healthcare cost puzzle, but it is among the most visible. Americans routinely encounter sticker shock at the pharmacy counter, making it a powerful political issue.
Experts say real reform will also require addressing structural inefficiencies, such as:
The role of pharmacy benefit managers (PBMs), who negotiate rebates behind closed doors.
Patent loopholes that extend monopolies on popular drugs.
Limited competition in the generic and biosimilar markets.
The Trump administration has signaled it may target PBMs next, accusing them of pocketing rebates that should lower costs for patients.
The next two months will be decisive. Pharmaceutical companies are expected to lobby aggressively, both behind the scenes in Washington and publicly through advertising campaigns warning of the risks of “price controls.”
At the same time, consumer advocacy groups are preparing to rally in support of the ultimatum, highlighting personal stories of families crushed by medical bills.
Trump, known for his combative style, appears ready for a public showdown. “We’re not asking,” he said during a recent event. “We’re telling them: lower your prices, or we’ll do it for you.”
The administration’s 60-day ultimatum sets the stage for one of the most consequential battles between the U.S. government and the pharmaceutical industry in modern history.
For patients, the outcome could mean hundreds—or even thousands—of dollars in annual savings. For drugmakers, it represents an existential threat to their current business model.
The fight over drug prices has simmered for decades. Now, with a firm deadline and the weight of the presidency behind it, the battle is moving to the forefront of national politics.
Whether this ultimatum produces meaningful reform or dissolves into another round of stalemate will shape not only the cost of medicine in America but also the balance of power between government and industry for years to come.
Los Angeles, July 2025 — Vice President Kamala Harris is once again at the center of speculation over her political future, following striking comments made by her longtime political mentor — and former romantic partner — Willie Brown, the ex-mayor of San Francisco.
Brown, now 91, remains an influential voice in California Democratic politics despite having left public office more than two decades ago. In a recent interview with podcaster Jon Slavet, the former mayor offered a blunt assessment of Harris’s career trajectory, suggesting that her next move might not include a run for governor — and perhaps should not.
Brown’s Surprising Admission
In a clip from the interview that has circulated widely, Brown did not mince words about Harris’s potential future in California politics.
“She may not want to run for governor of the state of California. That may not be where she should be going,” Brown told Slavet. “I think it’s going to be difficult for her to win that job.”
For Harris — who has served as a district attorney, attorney general of California, U.S. senator, and vice president — the comments land as both a personal and political jolt. Coming from someone who has been both a mentor and, decades ago, a romantic partner, Brown’s remarks carry more weight than the average pundit’s speculation.
A Mentor’s Perspective
Slavet, recounting his discussion with Brown during an appearance on Los Angeles anchor Elex Michaelson’s program, described the elder statesman as still sharp and candid at his advanced age.
“First of all, kudos to Willie — age 91, still going strong, still sharp. I mean, I think that’s amazing,” Slavet said. “He, in effect, said he doesn’t think governor is a fit for her.”
According to Slavet, Brown praised Harris’s background in the legal world but expressed doubts about her effectiveness as an executive leader.
“He talked about her strengths in the legal world, but not as an executive, which to me was pretty stunning because this is a guy who knows her very well,” Slavet noted. “He’s a legend in Democratic politics, right? He’s been a mentor to Kamala. And he actually cares about the future of California authentically, and he in effect said she should try something different.”
The Attorney General “What-If”
One of the more intriguing revelations from Brown was his claim that he had advised Harris against accepting the vice presidency when Joe Biden offered her the slot on his 2020 ticket.
According to Slavet, Brown chuckled as he recounted the moment. “He said, ‘I got in trouble for this when I said it.’ But what he told me is that when she was one of the final five and Biden was reviewing the final candidates, he recommended to her that she ask Biden to nominate her as attorney general instead.”
The reasoning, Brown reportedly explained, was simple: Harris’s skills as a prosecutor and legal strategist would shine in the role of the nation’s top law enforcement officer, while the vice presidency — a position often defined by its lack of clear responsibilities — risked diluting her political brand.
“She’s better in the legal world than as an executive,” Brown believed, according to Slavet.
A Complicated Relationship
Brown’s commentary is particularly striking given his personal history with Harris. The two were romantically linked in the mid-1990s, when Brown was speaker of the California State Assembly and Harris was beginning her legal career. While critics have long suggested that Harris benefited politically from the connection, she has consistently pushed back against attempts to reduce her career to that relationship.
Still, Brown has remained a fixture in discussions of Harris’s political journey — sometimes as a defender, other times as a critic. His latest remarks fall somewhere in between, acknowledging her talents but questioning her long-term political strategy.
Harris’s Political Dilemmas
Harris faces a unique set of challenges as she looks ahead. Her tenure as vice president has been marked by both historic firsts — as the first woman and the first person of both Black and South Asian descent to hold the office — and persistent criticisms.
Polling throughout Biden’s presidency often showed Harris with approval ratings lower than the president’s, a vulnerability that has dogged her since entering national office. Critics point to uneven messaging, high-profile missteps, and a perception that she has struggled to define her role within the administration.
Those weaknesses, Brown seemed to suggest, would make a run for California governor a risky move. Despite being Harris’s home state, California’s politics are notoriously complex, with fierce intra-party rivalries and an electorate that can be both deeply liberal and sharply pragmatic.
“She’d be walking into a hornet’s nest,” one California political strategist, who requested anonymity, said when asked about Brown’s comments. “There are already ambitious Democrats lining up for 2026 and beyond. Running for governor is not the safe bet some people think it is.”
Looking Beyond Sacramento
If Brown is correct that Harris should not pursue the governorship, the question becomes: what next?
Some observers believe Harris could still seek a return to the Senate, though that would require waiting for an opening in one of California’s seats. Others speculate she may angle for a Cabinet position in a future Democratic administration, particularly in the Justice Department, where her legal background would be most relevant.
There is also the possibility that Harris could position herself for another presidential run. While her 2020 campaign fizzled early, some allies believe her national profile as vice president gives her a stronger foundation should she try again in the future. Brown’s comments, however, cast doubt on whether such a move would play to her strengths.
Brown’s Legacy and Harris’s Future
At 91, Willie Brown has nothing to lose by speaking bluntly. Known for decades as a kingmaker in California politics, his reputation for savvy maneuvering remains intact. Whether his latest advice proves prescient or not, it underscores the uncertainty surrounding Harris’s political future.
For Harris, the stakes are high. After serving as vice president — one of the pinnacles of American politics — any step down could be seen as a setback. Yet Brown’s words serve as a reminder that ambition must be balanced with strategy, and that even a resume as trailblazing as hers does not guarantee success in every arena.
Conclusion
Kamala Harris stands at a crossroads. Her vice presidency cemented her place in history, but the path forward is far less clear. Should she heed her mentor’s advice and return to her legal roots? Or should she defy the doubts and pursue executive leadership in California or beyond?
What is certain is that her next move will be closely watched — not just by voters and pundits, but by her former mentor, who still seems invested in shaping the trajectory of a woman he once guided into the political spotlight.
As Brown himself put it: “She may not want to run for governor. That may not be where she should be going.”